VisionPoint Advisory Group’s Charles River Laboratories CRL Stock Holding History

VisionPoint Advisory Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,022	Closed	-$1.38M	–	485
2026 Q1	$1.38M	Sell	8,022 -616	-7%	-$114K	0.26%	93
2025 Q4	$1.72M	Sell	8,638 -1,195	-12%	-$217K	0.34%	81
2025 Q3	$1.54M	Sell	9,833 -3,661	-27%	-$581K	0.31%	88
2025 Q2	$2.05M	Buy	13,494 +3,815	+39%	+$509K	0.45%	62
2025 Q1	$1.46M	Buy	9,679 +90	+0.9%	+$15.1K	0.5%	57
2024 Q4	$1.75M	Buy	+9,589	New	+$1.85M	0.6%	51
2024 Q3	–	Sell	-160	Closed	-$33.1K	–	349
2024 Q2	$33.1K	Buy	160 +9	+6%	+$2.04K	0.01%	332
2024 Q1	$40.9K	Sell	151 -58	-28%	-$13.9K	0.01%	291
2023 Q4	$49.4K	Buy	209 +65	+45%	+$12.8K	0.02%	242
2023 Q3	$28.2K	Buy	144 +74	+106%	+$15.2K	0.01%	315
2023 Q2	$14.7K	Buy	+70	New	+$13.9K	0.01%	344

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

VisionPoint Advisory Group's CRL Position: Q2 2026 in Review

VisionPoint Advisory Group sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 8,022 shares — an estimated $1.38M sold.

VisionPoint Advisory Group first reported a position in CRL in Q2 2023 and held it in 11 quarters. The position peaked at $2.05M in Q2 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

VisionPoint Advisory Group reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
VisionPoint Advisory Group sold 8,022 Charles River Laboratories shares in Q2 2026, an estimated $1.38M.
VisionPoint Advisory Group first reported a position in Charles River Laboratories in Q2 2023 and held it in 11 quarters.
VisionPoint Advisory Group's Charles River Laboratories position peaked at $2.05M in Q2 2025.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.